Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-06-2009 | Cataract

Polylactide-glycoli acid and rapamycin coating intraocular lens prevent posterior capsular opacification in rabbit eyes

Authors: Hongling Liu, Lan Wu, Shaoying Fu, Yongsheng Hou, Ping Liu, Hao Cui, Jingjing Liu, Lin Xing, Xiaomei Zhang

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2009

Abstract

Objectives

Posterior capsular opacification (PCO) is caused by the proliferation and migration of residual lens epithelium cells (LECs) after extracapsular cataract extraction (ECCE). Rapamcin (RAPA) is known to be a potent immunosuppressive drug with anti-inflammatory and anti-proliferative effects. The aim of this study was to investigate the safety and efficacy of rapamycin sustained release from modified intraocular lens (IOLs) in the prevention of PCO in rabbits.

Methods

Three types of IOLs were used, including the original IOL without modification, IOL with polylactide-glycoli acid (PLGA) coating (PLGA-IOL), and RAPA-loaded PLGA-IOL (RAPA-PLGA-IOL). Sixty New Zealand albino rabbits undergoing phacoemulsification in left eyes were randomly and equally divided into three groups. Group A was implanted with the original IOLs, group B was implanted with the PLGA-IOLs, and group C was implanted with the RAPA-PLGA-IOLs. All of the 60 treated left eyes were examined by a slit-lamp microscope. The concentrations of RAPA in the aqueous humor and blood were determined by high-performance liquid chromatography (HPLC), indicating an vivo release of drug from the polymer carrier. Anterior segment tissue was histologically examined, and wet posterior capsules were weighed. Six months after intervention the PCO was graded.

Results

The mean concentrations of RAPA in the aqueous humor from group C at 2 h, 1 days, 3 days, and 7 days after operation were 12.81 ± 1.27 μg/ml, 14.57 ± 0.99 μg/ml, 6.39 ± 0.95 μg/ml, and 1.10 ± 0.32 μg /ml respectively. The concentrations of RAPA in blood were undetectable. During the early days after the operation, the reactions of the anterior chamber from groups A and B were more severe than from group C. Our findings showed that the initial appearance of PCO in group C was much later than in the other two groups. The wet posterior capsules were weighed to be 0.3735 ± 0.0943 g (group A), 0.3754 ± 0.1093 g (group B), and 0.0432 ± 0.0089 g (group C). Histological observation showed a similar phenomenon, that there was remarkably less accumulation of lens materials on the posterior capsules in group C than in the other two groups.

Conclusion

Our findings suggest that the designed RAPA-PLGA-IOL effectively prevented formation and development of PCO for a relatively long duration.

Stark WJ, Sommer A, Smith RE (1989) Changing trends in intraocular lens implantation. Arch Ophthalmol 107:1441–1444PubMed

Ohrloff C, Schalnus R, Rothe R, Spitznas M (1990) Role of the posterior capsule in the aqueous-vitreous barrier in aphakic and pseudophakic eyes. J Cataract Refract Surg 16:198–201PubMed

McDonnell PJ, Patel A, Green WR (1985) Comparison of intracapsular and extracapsular cataract surgery. Histopathologic study of eyes obtained postmortem. Ophthalmology 92:1208–1225PubMed

Schaumberg DA, Dana MR, Christen WG, Glynn RJ (1998) A systematic overview of the incidence of posterior capsule opacification. Ophthalmology 105:1213–1221. doi:10.1016/S0161-6420(98)97023-3 PubMedCrossRef

Apple DJ, Solomon KD, Tetz MR, Assia EI, Holland EY, Legler UF, Sai JC, Castaneda VE, Hoggatt JP, Kostick AM (1992) Posterior capsule opacification. Surv Ophthalmol 37:73–116. doi:10.1016/0039-6257(92)90073-3 PubMedCrossRef

Kappelhof JP, Vrensen GF (1992) The pathology of after-cataract. A minireview. Acta Ophthalmol Suppl 205:13–24PubMed

Gao X, Cai KL, Wu XL, Yang XL, Huo W (2006) Rapamycin inhibits the pathogenesis of posterior capsule opacification experimental study on rabbit. J Shandong Univ 6:634–637

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, SIRIUS Investigators (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315–1323. doi:10.1056/NEJMoa035071 PubMedCrossRef

Yang P, Li S (1998) Uveitis. People’s Medical Publishing House, Beijing

10.

Hepsen IF, Bayramlar H, Gültek A, Özen S, Tilgen F, Evereklioglu C (1997) Caffeic acid phenethyl ester to inhibit posterior capsule opacification in rabbits. J Cataract Refract Surg 23:1572–1576PubMed

11.

Cobo LM, Ohsawa E, Chandler D, Arguello R, George G (1984) Pathogenesis of capsular opacification after extracapsular cataract extraction. An animal model. Ophthalmology 91:857–863PubMed

12.

Frezzotti R, Caporossi A (1990) Pathogenesis of posterior capsule opacification. I. Epidemiological and clinicostatistical data. J Cataract Refract Surg 16:347–352PubMed

13.

Frezzotti R, Caporossi A, Mastrengelo D, Hadjistilianou T, Tosi P, Cintorino M, Minacci C (1990) Pathogenesis of posterior capsule opacification. II. Histopathological and in vitro culture findings. J Cataract Refract Surg 16:353–360PubMed

14.

Green WR, McDonnell PJ (1985) Opacification of the posterior capsule. Trans Ophthalmol Soc U K 104:727–739PubMed

15.

McDonnell PJ, Stark WJ, Green WR (1984) Posterior capsule opacification: a specular microscopic study. Ophthalmology 91:853–856PubMed

16.

McDonnell PJ, Krause W, Glaser BM (1988) In vitro inhibition of lens epithelial cell proliferation and migration. Ophthalmic Surg 19:25–30PubMed

17.

Hansen TJ, Tyndall R, Soll DB (1987) Methotrexate-anticollagen conjugate inhibits in vitro lens cell outgrowth. Invest Ophthalmol Vis Sci 28:1206–1209PubMed

18.

Sehgal SN, Baker H, Vézina C (1975) Rapamycin (AY-22,989), A new antifungal antibiotic: II. Fermentation, isolation, and characterization. J Antibiot 28:727–732PubMed

19.

Vézina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989). A new antifungal antibiotic: I. Toxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 28:721–726PubMed

20.

Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ (2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188–1193. doi:10.1161/hc3601.093987 PubMedCrossRef

21.

Gummert JF, Ikonen T, Morris RE (1999) Newer immunosuppressive drugs: a review. J Am Soc Nephrol 10:1366–1380PubMed

22.

Marx SO, Jayaraman T, Go LO, Marks AR (1995) Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76:412–417PubMed

23.

Zhao J, Cai KL (2007) Effects of rapamycin on regeneration of cultured rabbit lens epithelial cells. Chin J Optom Ophthalmol 9:37–39

24.

Regar E, Sianos G, Serruys PW (2001) Stent development and local drug delivery. Br Med Bull 59:227–248. doi:10.1093/bmb/59.1.227 PubMedCrossRef

25.

Klingemann HG (1995) Update on immunosuppressive drugs (A report from the International Consensus Conference on Immunosuppressive Drugs). DN&P 8:303–309

26.

Ohia EO, Mancino M, Kulkarni PS (1992) Effects of steroids and immunosuppressive drug on endotoxin-uveitis in rabbits. J Ocul Pharmacol 8:295–307PubMedCrossRef

27.

Nishi O, Nishi K, Imanishi M, Tada Y, Shirasawa E (1995) Effect of the cytokines on the prostaglandin E2 synthesis by lens epithelial cells of human cataracts. Br J Ophthalmol 79:934–938. doi:10.1136/bjo.79.10.934 PubMedCrossRef

28.

Roberge FG, Xu D, Chan CC, de Smet MD, Nussenblatt RB, Chen H (1993) Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr Eye Res 12:197–203. doi:10.3109/02713689308999487 PubMedCrossRef

29.

Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J (2004) Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 10:964–972PubMed

30.

Chan CC, Martin DF, Xu D, Roberge FG (1995) Side effects of rapamycin in the rat. J Ocul Pharmacol Ther 11:177–181PubMedCrossRef

31.

Buech G, Bertelmann E, Pleyer U, Siebenbrodt I, Borchert HH (2007) Formulation of sirolimus eye drops and corneal permeation studies. J Ocul Pharmacol Ther 23:292–303. doi:10.1089/jop.2006.130 PubMedCrossRef

32.

Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ogura Y (2002) Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits. Graefes Arch Clin Exp Ophthalmol 240:672–678. doi:10.1007/s00417-002-0484-9 PubMedCrossRef

33.

Nishi O, Nishi K, Yamada Y, Mizumoto Y (1995) Effect of indomethacin-coated posterior chamber intraocular lenses on postoperative inflammation and posterior capsule opacification. J Cataract Refract Surg 21:574–578PubMed

34.

Kwon YS, Kim JC (2006) Inhibition of corneal neovascularization by rapamycin. Exp Mol Med 38:173–179PubMed

35.

Shi W, Gao H, Xie L, Wang S (2006) Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci 47:3339–3344. doi:10.1167/iovs.05-1425 PubMedCrossRef

Title: Polylactide-glycoli acid and rapamycin coating intraocular lens prevent posterior capsular opacification in rabbit eyes
Authors: Hongling Liu
Lan Wu
Shaoying Fu
Yongsheng Hou
Ping Liu
Hao Cui
Jingjing Liu
Lin Xing
Xiaomei Zhang
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2009
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-008-1007-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Polylactide-glycoli acid and rapamycin coating intraocular lens prevent posterior capsular opacification in rabbit eyes

Abstract

Objectives

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2009

Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT)

Distance doubling visual acuity test: A reliable test for nonorganic visual loss

Relationship between anterior corneal asphericity and refractive variables

Lack of association of VEGF (−2578 C → A) and ANG 2 (−35 G → C) gene polymorphisms with the progression of retinopathy of prematurity

Down-regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering RNA (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in rats

The evaluation of the treatment response in obstructive meibomian gland disease by in vivo laser confocal microscopy